[{"address1": "630 5th Avenue", "address2": "20th Floor", "city": "New York", "state": "NY", "zip": "10111", "country": "United States", "phone": "844 689 3939", "website": "https://www.anavex.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp.was incorporated in 2004 and is headquartered in New York, New York.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher U. Missling M.B.A., M.S., Ph.D.", "age": 58, "title": "President, CEO, Secretary & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 856100, "exercisedValue": 0, "unexercisedValue": 10940450}, {"maxAge": 1, "name": "Ms. Sandra  Boenisch CPA, CGA", "age": 43, "title": "Principal Financial Officer & Treasurer", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 209527, "exercisedValue": 0, "unexercisedValue": 553580}, {"maxAge": 1, "name": "Dr. Walter E. Kaufmann M.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Clint  Tomlinson", "title": "VP of Corporate", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Adebayo  Laniyonu Ph.D.", "title": "Senior Vice President of Nonclinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edward R Hammond M.D., M.P.H., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kun  Jin Ph.D.", "title": "Head of Biostatistics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Goldberger R.Ph.", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Terrie  Kellmeyer Ph.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juan Carlos  Lopez-Talavera M.D., Ph.D.", "title": "Senior VP & Head of Research and Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 7, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 8.47, "open": 8.53, "dayLow": 8.45, "dayHigh": 8.95, "regularMarketPreviousClose": 8.47, "regularMarketOpen": 8.53, "regularMarketDayLow": 8.45, "regularMarketDayHigh": 8.95, "beta": 0.687, "forwardPE": 1.651163, "volume": 823678, "regularMarketVolume": 823678, "averageVolume": 1806716, "averageVolume10days": 1119050, "averageDailyVolume10Day": 1119050, "bid": 6.29, "ask": 10.93, "bidSize": 200, "askSize": 200, "marketCap": 724747008, "fiftyTwoWeekLow": 3.25, "fiftyTwoWeekHigh": 14.441, "fiftyDayAverage": 9.7912, "twoHundredDayAverage": 6.6298, "currency": "USD", "enterpriseValue": 603971968, "floatShares": 82474845, "sharesOutstanding": 85064200, "sharesShort": 23425067, "sharesShortPriorMonth": 21800438, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.2762, "heldPercentInsiders": 0.03063, "heldPercentInstitutions": 0.35034, "shortRatio": 12.49, "shortPercentOfFloat": 0.2849, "impliedSharesOutstanding": 85064200, "bookValue": 1.305, "priceToBook": 6.528736, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -46491000, "trailingEps": -0.55, "forwardEps": -0.63, "lastSplitFactor": "1:4", "lastSplitDate": 1444176000, "52WeekChange": 0.5802239, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AVXL", "underlyingSymbol": "AVXL", "shortName": "Anavex Life Sciences Corp.", "longName": "Anavex Life Sciences Corp.", "firstTradeDateEpochUtc": 1154525400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a192134c-09ce-387b-bb62-3b271f6333ed", "messageBoardId": "finmb_13580387", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.52, "targetHighPrice": 42.0, "targetLowPrice": 15.0, "targetMeanPrice": 32.63, "targetMedianPrice": 40.89, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 120775000, "totalCashPerShare": 1.42, "quickRatio": 9.395, "currentRatio": 9.449, "returnOnAssets": -0.24337, "returnOnEquity": -0.37722, "freeCashflow": -22235500, "operatingCashflow": -35614000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]